USE OF INTESTINAL PROBIOTIC IN PREPARATION OF MEDICAMENT THAT PROMOTES METABOLISM OF ELLAGIC ACID INTO UROLITHIN A, PHARMACEUTICAL COMPOSITION AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Nov 21, 2024
app pub date -
Aug 2, 2023
filing date -
Aug 2, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure provides use of an intestinal probiotic in preparation of a medicament that promotes metabolism of ellagic acid (EA) into urolithin A, a pharmaceutical composition and use thereof, and belongs to the technical field of biomedicine. In the present disclosure, probiotics capable of changing metabotypes of EA are selected from a plurality of probiotics. These probiotics alone or in combination can change an intestinal flora structure of a metabotype B and/or 0 population, thereby improving the efficiency of the metabolism of EA into urolithin A and increasing a yield of urolithin A. The present disclosure provides an intestinal probiotic for involving in and promoting the metabolism of EA into urolithin A, and provides a new idea for the treatment of diabetes, obesity, senescence, and diseases caused by central nervous system lesions and viral infection using urolithin A as an active pharmaceutical ingredient.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully